Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam R Ward

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The Journal of Clinical Investigation|January 23, 2018
Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cellsSzu-Han Huang, Yanqin Ren, Allison S Thomas, et al.
JCI Insight|August 15, 2023
The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cellsDennis C Copertino, Carissa S Holmberg, Jared Weiler, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1Marta Sanz, Ann Marie K Weideman, Adam R Ward, et al.
Frontiers in Immunology|September 25, 2023
Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1Marta Sanz, Ann Marie K Weideman, Adam R Ward, et al.
JCI Insight|January 5, 2021
HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapyEva M Stevenson, Adam R Ward, Ronald Truong, et al.
Cell Reports|May 7, 2025
EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8<sup>+</sup> T cells toward less-exhausted phenotypesAndrea Gramatica, Itzayana G Miller, Adam R Ward, et al.
Nature Communications|August 19, 2022
SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8<sup>+</sup> T-cellsEva M Stevenson, Sandra Terry, Dennis Copertino, et al.
Nature Medicine|October 17, 2022
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trialJesper D Gunst, Marie H Pahus, Miriam Rosás-Umbert, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Journal of Clinical Investigation|January 23, 2018
Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cellsSzu-Han Huang, Yanqin Ren, Allison S Thomas, et al.
JCI Insight|August 15, 2023
The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cellsDennis C Copertino, Carissa S Holmberg, Jared Weiler, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1Marta Sanz, Ann Marie K Weideman, Adam R Ward, et al.
Frontiers in Immunology|September 25, 2023
Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1Marta Sanz, Ann Marie K Weideman, Adam R Ward, et al.
JCI Insight|January 5, 2021
HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapyEva M Stevenson, Adam R Ward, Ronald Truong, et al.
Cell Reports|May 7, 2025
EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8<sup>+</sup> T cells toward less-exhausted phenotypesAndrea Gramatica, Itzayana G Miller, Adam R Ward, et al.
Nature Communications|August 19, 2022
SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8<sup>+</sup> T-cellsEva M Stevenson, Sandra Terry, Dennis Copertino, et al.
Nature Medicine|October 17, 2022
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trialJesper D Gunst, Marie H Pahus, Miriam Rosás-Umbert, et al.
Pageof 2